熱門資訊> 正文
GoodRx推出每月39美元的减肥远程医疗订阅
2025-11-17 21:50
- GoodRx (GDRX) announced two major initiatives on Monday to make FDA-approved GLP-1 medications more widely available.
- First, the launch of GoodRx for Weight Loss, a telemedicine subscription that connects consumers to licensed healthcare providers for affordable weight management treatment.
- Second, in partnership with Novo Nordisk, a new introductory cash price of $199 per month for Ozempic and Wegovy injection pens available to GoodRx users.
- The GoodRx for Weight Loss telemedicine subscription is available for an introductory rate of $39 per month through January 2026, with a standard price of $119 beginning on February 1, 2026.
More on GoodRx Holdings
- GoodRx Holdings, Inc. (GDRX) Q3 2025 Earnings Call Transcript
- GoodRx: Novo Deal And TrumpRx Talks Point To Ebitda/FCF Upside
- GoodRx: Renewed Chance To Sign Up New Customers
- GoodRx won't be participating with TrumpRx: report
- GoodRx outlines 35% manufacturer solutions growth for 2025 while expanding direct-to-consumer initiatives
推薦文章
美股機會日報 | 估值8500億美元！傳OpenAI最新融資規模將破千億美元；黃仁勛稱將發佈幾款世界前所未見的新芯片
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
